Nelson NH Teng MD, PhD, FACOG, FACSDirector of Gynecologic Oncology and Associate Professor of Obstetrics and Gynecology, Stanford University School of Medicine; Program Director for the Stanford/UCSF Gynecologic Oncology Fellowship Program; Stanford, California
Dr. Nelson Teng received a PhD in biophysics from the University of California at Berkeley and subsequently earned a medical degree from the University of Miami, School of Medicine, in Florida. He completed a fellowship in gynecologic oncology at Stanford University School of Medicine.
Dr. Teng is an active member of professional associations and societies, serving as chairman of the Uterine/Cervix Committee of the National Comprehensive Cancer Network and on various committees of the Gynecologic Oncology Group, among other positions. He has also been the executive director of the Asia program of Medicine for Humanity.
Dr. Teng heads a basic science research laboratory in which he investigates the role of monoclonal antibodies in cancer. His main areas of research interest are immunology and tumor biology. In addition, he is interested in translational and clinical studies in gynecologic malignancies. He holds more than 20 patents. His research findings have been published in more than 130 articles, and he has authored nearly 20 book chapters.
Throughout his career, Dr. Teng’s knowledge and expertise have been recognized by numerous awards and honors. In 1997, Stanford awarded him the Inventor Recognition Award and the Resident Teaching Award. He has been a scientific advisor and mentor to many researchers, including PhD candidates, residents, fellows, and medical students. The International Biographical Centre of Cambridge, England, named him Outstanding Scientist of the 21st Century in 2000, and, in 2001, he was selected as one of America's Top Doctor by the Association of Academic Health Centers.
Director of Gynecologic Oncology and Associate Professor of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California
PhD (biophysics): University of California at Berkeley
MD: University of Miami, School of Medicine, Florida
Fellowship (gynecologic oncology): Stanford University School of Medicine; Stanford, California
Monoclonal antibodies in cancer; immunology and tumor biology; translational and clinical studies in gynecologic malignancies
Recent Contributions to PracticeUpdate:
- Bevacizumab Breaks Ground in Cervical Cancer
- Dr. Nelson Teng's ASCO Take-Home Messages—Gynecologic Cancers
- Cisplatin-Based IP Chemotherapy Associated With Improved Survival in BRCA1+ Ovarian Cancer
- Top Stories of 2012: Role of Bevacizumab in Late-Stage Ovarian Cancer
- Platinum Resistance After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
- Bevacizumab Effective in Platinum-Sensitive Recurrent Ovarian Cancer
- Ovarian Cancer—New Thinking on Old Regimens